Molecular Partners (NASDAQ:MOLN) Given Buy Rating at HC Wainwright

Molecular Partners (NASDAQ:MOLN)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $13.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 208.06% from the company’s current price.

Several other equities analysts also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a report on Monday, December 22nd. JPMorgan Chase & Co. cut their price objective on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research report on Monday, December 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.38.

Molecular Partners Trading Down 10.4%

NASDAQ:MOLN opened at $4.22 on Monday. The stock has a 50-day moving average price of $4.54 and a 200 day moving average price of $4.18. The stock has a market capitalization of $170.40 million, a P/E ratio of -2.12 and a beta of 1.03. Molecular Partners has a 12-month low of $3.36 and a 12-month high of $5.36.

Molecular Partners (NASDAQ:MOLN) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). On average, research analysts predict that Molecular Partners will post -1.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Molecular Partners

An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors own 26.55% of the company’s stock.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.